Awarded
PHE - Corporate - Newborn Screening for Cystic Fibrosis
£99,696
services
Contract Details
- Tender Value
- £99,696
- Stage
- Awarded
- Published
- Awarded
Timeline
Awarded
Start
Disclosed
End
Description
Determining the impact of employing next generation genomic sequencing (NGS) as part of the method of newborn screening for Cystic Fibrosis (CF): a stakeholder engagement project
Related Contracts
From This Buyer
- Quality control and assurance services
£500,000 ·
- Egress Protect and Egress Workspace licences
£561,600 ·
- Tenable - Vulnerability Monitoring solution
£383,572 ·
- Provision of Colony Counter ProtoCOL 3 PLUS
£16,092 ·
From This Supplier
In This Category
Ref: e3b933cf-856b-4d2a-9daf-b7cb57f9696a-482698 · Sourced from Contracts Finder
View source notice